{"id":"https://openalex.org/W3009707110","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","title":"Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer","display_name":"Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer","publication_year":2020,"publication_date":"2020-02-15","ids":{"openalex":"https://openalex.org/W3009707110","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","mag":"3009707110"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs19-p2-05-07","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000509598","display_name":"Martina S.J. McDermott","orcid":"https://orcid.org/0000-0001-5737-7202","observed_orcids":["https://orcid.org/0000-0001-5737-7202"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martina SJ McDermott","raw_affiliation_strings":["UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045387212","display_name":"Dylan F. Conklin","orcid":"https://orcid.org/0000-0003-4708-0071","observed_orcids":["https://orcid.org/0000-0003-4708-0071"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dylan F Conklin","raw_affiliation_strings":["UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028010756","display_name":"Neil A. O\u2019Brien","orcid":"https://orcid.org/0000-0001-7408-1091","observed_orcids":["https://orcid.org/0000-0001-7408-1091"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil A O'Brien","raw_affiliation_strings":["UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063951168","display_name":"Kevin Chau","orcid":"https://orcid.org/0000-0001-9945-9169","observed_orcids":["https://orcid.org/0000-0001-9945-9169"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Chau","raw_affiliation_strings":["UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis J Slamon","raw_affiliation_strings":["UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I161318765"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"4_Supplement","first_page":"P2","last_page":"05"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9419999718666077},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8519999980926514},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.8899999856948853},{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.7160000205039978},{"id":"https://openalex.org/keywords/poly-adp-ribosyl-ation","display_name":"poly(ADP-ribosyl)ation","score":0.8090000152587891},{"id":"https://openalex.org/keywords/g2-cell-cycle-arrest","display_name":"G2 cell cycle arrest","score":0.7170000076293945},{"id":"https://openalex.org/keywords/cancer-cell-lines","display_name":"cancer cell lines","score":0.656000018119812},{"id":"https://openalex.org/keywords/patient-selection-criteria","display_name":"patient selection criteria","score":0.6990000009536743},{"id":"https://openalex.org/keywords/parp-trapping","display_name":"PARP trapping","score":0.5849999785423279},{"id":"https://openalex.org/keywords/dna-nicks","display_name":"DNA nicks","score":0.6819999814033508},{"id":"https://openalex.org/keywords/unmet-medical-needs","display_name":"unmet medical needs","score":0.5929999947547913}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9630945920944214},{"id":"https://openalex.org/C2778480876","wikidata":"https://www.wikidata.org/wiki/Q21112674","display_name":"PARP1","level":5,"score":0.8401085138320923},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.8007423877716064},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.604823648929596},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5879454016685486},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5749693512916565},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5628378391265869},{"id":"https://openalex.org/C2781312401","wikidata":"https://www.wikidata.org/wiki/Q7919041","display_name":"Veliparib","level":5,"score":0.5069132447242737},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.49694231152534485},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.49044033885002136},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.4622580409049988},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.44760602712631226},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43131983280181885},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.413546085357666},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3372184634208679},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.3075186312198639},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2963942587375641},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.18208923935890198},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.12016889452934265},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs19-p2-05-07","doi":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs19-p2-05-07","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2080385145","https://openalex.org/W2604158559","https://openalex.org/W2589593521","https://openalex.org/W1989389011","https://openalex.org/W2756935441","https://openalex.org/W7100039513","https://openalex.org/W2042660215","https://openalex.org/W2328979501","https://openalex.org/W2022309076","https://openalex.org/W2045091545"],"abstract_inverted_index":{"Abstract":[0],"The":[1,25,48,223,274],"development":[2,50,343],"of":[3,14,19,28,40,51,81,128,153,226,250,254,258,267,287,304,318,344,373,379,392],"multiple":[4],"PARP":[5,41,52,91,305,326,374],"inhibitors":[6,42,53,122,306,327],"in":[7,23,30,99,134,196,210,229,277,291,328,386],"BRCA":[8,31,45],"mutant":[9],"cancers":[10,34],"has":[11],"been":[12],"one":[13,266],"the":[15,36,121,187,248,268,285,292,301,340,393],"most":[16,269],"successful":[17,49],"implementations":[18],"molecularly":[20],"targeted":[21],"therapies":[22],"oncology.":[24],"recent":[26],"approval":[27],"niraparib":[29],"WT":[32,46],"Ovarian":[33],"demonstrates":[35],"potential":[37],"for":[38,86,240,272,300,323,339],"expansion":[39],"to":[43,64,88,113,144,161,167,182,202,207,216,236,246,307,325],"other":[44],"indications.":[47],"into":[54,242,256,347],"new":[55],"cancer":[56,83,176,264,330,388],"indications":[57],"will":[58],"depend":[59],"on":[60,71],"using":[61],"molecular":[62,224],"biomarkers":[63,290,319,380],"identify":[65],"tumors":[66],"with":[67,165,205,218,351,383],"a":[68,76,104,124,131,316,377],"unique":[69],"dependency":[70],"PARP1/2":[72,168,208,384],"activity.":[73],"We":[74],"screened":[75],"large":[77],"(N=523),":[78],"diverse":[79],"panel":[80,317],"human":[82],"cell":[84,111,149],"lines":[85,112],"response":[87,166,206,227],"three":[89,115],"approved":[90,189],"inhibitors:":[92],"olaparib,":[93],"niraparib,":[94],"and":[95,109,147,156,170],"talazoparib.":[96],"Despite":[97],"differences":[98],"relative":[100],"potency,":[101],"there":[102],"was":[103,180],"strong":[105],"correlation":[106],"between":[107,174],"sensitive":[108],"resistant":[110],"all":[114],"compounds.":[116],"In":[117,311],"vitro":[118],"experimentation":[119],"revealed":[120],"share":[123],"similar":[125],"biologic":[126],"mechanism":[127],"response,":[129],"namely":[130],"global":[132],"decrease":[133],"PARylation,":[135],"as":[136,138,335],"well":[137],"PARP-trapping":[139],"at":[140],"DNA":[141],"nicks":[142],"leading":[143],"G2":[145],"arrest":[146],"ultimately":[148,233],"death.":[150],"A":[151,364],"suite":[152,378],"baseline":[154],"genomic":[155],"proteomic":[157],"characteristics":[158],"were":[159,171,200],"found":[160,201],"be":[162,203,234,281,333],"strongly":[163],"associated":[164,204],"inhibition,":[169],"largely":[172],"consistent":[173],"different":[175],"types.":[177],"Special":[178],"attention":[179],"paid":[181],"BRCA1/2":[183],"variants,":[184],"which":[185],"represent":[186],"only":[188],"patient":[190,336,349],"selection":[191,337],"biomarkers.":[192],"Notably,":[193],"neither":[194],"mutations":[195],"BRCA1":[197],"nor":[198],"BRCA2":[199],"inhibition":[209,375],"our":[211,230],"panel,":[212],"even":[213],"when":[214],"restricting":[215],"those":[217],"confirmed":[219],"deleterious":[220],"ClinVar":[221],"scores.":[222],"predictors":[225],"identified":[228,315],"screen":[231],"may":[232,280,297],"used":[235,334],"develop":[237],"diagnostic":[238],"tools":[239],"enrollment":[241],"biomarker-enriched":[243],"clinical":[244,275,342],"trials":[245],"expand":[247],"use":[249],"this":[251,278],"promising":[252],"class":[253],"drug":[255],"areas":[257],"high":[259,352],"unmet":[260,353],"need.":[261,354],"Triple-negative":[262],"breast":[263,309,329,387],"represents":[265],"intriguing":[270],"spaces":[271],"development.":[273],"failures":[276],"space":[279],"partially":[282],"explained":[283],"by":[284],"lack":[286],"empirical":[288],"predictive":[289],"trial":[293],"design.":[294],"Our":[295],"diagnostics":[296],"finally":[298],"allow":[299],"efficacious":[302],"deployment":[303],"triple-negative":[308],"cancer.":[310],"particular":[312],"we":[313],"have":[314],"that":[320,331,381],"can":[321],"predict":[322],"sensitivity":[324],"could":[332],"criteria":[338],"expanded":[341],"these":[345],"compounds":[346],"PARP-na\u00efve":[348],"populations":[350],"Citation":[355],"Format:":[356],"Martina":[357],"SJ":[358],"McDermott,":[359],"Dylan":[360],"F":[361],"Conklin,":[362],"Neil":[363],"O'Brien,":[365],"Kevin":[366],"Chau,":[367],"Dennis":[368],"J":[369],"Slamon.":[370],"Pan-cancer":[371],"analysis":[372],"reveals":[376],"correlate":[382],"activity":[385],"[abstract].":[389],"In:":[390],"Proceedings":[391],"2019":[394,400],"San":[395,403],"Antonio":[396],"Breast":[397],"Cancer":[398,409],"Symposium;":[399],"Dec":[401],"10-14;":[402],"Antonio,":[404],"TX.":[405],"Philadelphia":[406],"(PA):":[407],"AACR;":[408],"Res":[410],"2020;80(4":[411],"Suppl):Abstract":[412],"nr":[413],"P2-05-07.":[414]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2020-03-13T00:00:00"}